

Fusilev[®] will no longer require prior authorization, starting May 31

Because Spectrum Pharmaceuticals has stopped manufacturing Fusilev (levoleucovorin), HCPCS code J0641, we'll no longer require prior authorization through AIM Specialty Health[®] for dates of service on or after May 31, 2022. The drug was part of members' medical benefits, not their pharmacy benefits.

This change applies to:

- Blue Cross and Blue Shield of Michigan commercial
 - Members who have coverage through fully insured groups
 - Members with individual coverage
 - UAW Retiree Medical Benefits Trust members with Blue Cross non-Medicare plans
- Medicare Plus BlueSM members
- Blue Care Network commercial members
- BCN AdvantageSM members

For additional information on requirements related to drugs covered under the medical benefit, refer to the following drug lists:

- Blue Cross and BCN commercial members:
 - [Medical oncology prior authorization list for Blue Cross commercial fully insured and BCN commercial members](#)
 - [Blue Cross and BCN utilization management medical drug list](#)
- URMBT members with Blue Cross non-Medicare plans:
 - [Medical oncology prior authorization list for UAW Retiree Medical Benefits Trust PPO non-Medicare members](#)
 - [Medical Drug Management with Blue Cross for UAW Retiree Medical Benefit Trust PPO non-Medicare Members](#)

Note: Accredo manages prior authorization requests for additional medical benefit drugs for these members.

- Medicare Plus Blue and BCN Advantage members: [Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue and BCN Advantage members](#)

We'll update the pertinent drug lists to reflect the information in this message prior to the effective date.